Key result
Transgender and gender-diverse individuals face elevated cardiovascular risk driven by minority stress and hormone therapy.
Why the study?
Transgender and gender-diverse individuals face an increased risk of adverse cardiovascular health outcomes, and the Tijuana Declaration urged the global cardiovascular community to work toward understanding and mitigating the factors that lead to this problem.
Answers are grounded in this paper and cite their sources.
Mitigating the disproportionately high cardiovascular risk in transgender and gender-diverse individuals requires medical education reform, inclusive clinical research on hormone therapies, and broader social initiatives to reduce minority stress and stigma.
On World Heart Day 2022, the Mexican Society of Cardiology, the Inter-American Society of Cardiology, and the World Heart Federation collaborated on a communication regarding the increased risk of adverse cardiovascular health outcomes in transgender and gender-diverse (TGD) individuals. This document, called the Tijuana Declaration, urged the global cardiovascular community to work toward understanding and mitigating this problem. This article aims to unpack the numerous factors that lead to it. An example is the social stigma faced by members of the TGD community, which leads to increased stress and risk for cardiovascular complications. TGD patients are also more likely to have insufficient access to health care, and those that do receive care are often faced with providers that are not adequately educated about the unique needs of their community. Finally, there is some evidence to suggest that gender-affirming hormone therapies have an impact on cardiovascular health, but studies on this subject often have methodological concerns and contradictory findings. Decreasing the incidence of adverse cardiovascular events in this community requires interventions such as educational reform in the medical community, an increase in research studies on this topic, and broader social initiatives intended to reduce the stigma faced by TGD individuals.
No takes yet. Share an insight, caveat, or question.
Cossío-Aranda et al. (2023) conducted a review in Cardiovascular disease risk in transgender and gender-diverse (TGD) individuals. Gender-affirming hormone therapy, social stigma/minority stress, and healthcare access disparities was evaluated on Adverse cardiovascular health outcomes (including myocardial infarction and venous thromboembolism). Transgender and gender-diverse individuals face elevated cardiovascular risk driven by minority stress, limited healthcare access, and potential effects of gender-affirming hormone therapy.